{
  "report_rows": [
    {
      "kpi": "Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$5.95B vs. cons $5.825B (+2.1%)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Operating EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$2.92 vs. cons $2.848 (+2.5%)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Book-to-Bill (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~1.35x vs. cons 1.11x (+22%)",
      "confidence": "HIGH"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Revenue FY2026 (FY)",
      "prediction": "BETTER",
      "answer": "guide ~$23.5-24.0B vs. cons $23.61B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Operating EPS FY2026 (FY)",
      "prediction": "BETTER",
      "answer": "guide ~$11.70-11.90 vs. cons $11.85",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Segment Op. Margin FY2026 (FY)",
      "prediction": "UNCHANGED",
      "answer": "guide 'low 16%' maintained vs. cons 14.56%",
      "confidence": "HIGH"
    },
    {
      "kpi": "FCF FY2026 (FY)",
      "prediction": "UNCHANGED",
      "answer": "guide ~$3.0B maintained vs. cons $2.94B",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 2.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 4.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 H2 estimate revisions positive; AXYV IPO update adds multiple catalyst; revision cycle turns constructive",
  "day5_confidence": "MEDIUM"
}